For AI assistants & researchers — machine-readable summary of this page
What this page is: Delvantic's full research page for Wells Fargo & Company (WFC) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.
Our current read (analysis of 2026-08-23): Designation Low · Gem Score -23 (−100…+100 Quality+Value blend) · Quality 32 · Value -68 · Sentiment -8 (timing only, not weighted) · Composite fair value $84.84 vs $86.45 at analysis
Page map (sections in order; each card carries a stable
reference-name attribute you can cite):
profile-header/price-overview— company profile, live quote, market capextended-analysis— the core: three AI lens reads with findings, scores, and the analyst memofuture-predictions— our forward price-band predictionsmarket-narrative/ai-findings/gpt-critique— narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)- Members-only sections (render as login gates for anonymous readers):
price-history,income-trend,key-metrics,financials(statement tables),insider-trading. The analysis above is public; the raw data tables require a free account.
More for machine readers: site briefing at
/llms.txt ·
any ticker resolves at delvantic.com/stock/TICKER ·
raw inputs are public-company filings and market data (via licensed data feeds);
every model, score, lens read, and prediction on this page is Delvantic's own analysis.
Wells Fargo & Company
WFC NYSEWells Fargo & Company is a diversified financial services company that provides banking, lending, wealth management, and capital markets solutions to consumers, small businesses, commercial clients, and institutional customers. Wells Fargo & Company operates through four main business segments: Consumer Banking and Lending, Commercial Banking, Corporate and Investment Banking, and Wealth and Investment Management. Its offerings include checking and savings accounts, credit cards, mortgages, auto loans, commercial lending, treasury management, advisory services, and investment products. The company also serves clients through branch networks, digital banking platforms, and specialized financial services channels, making it an important participant in U.S. retail and commercial banking. Headquartered in San Francisco, Wells Fargo & Company plays a significant role in the broader financial system by supporting everyday banking needs, business financing, and wealth-related services across the market.
Price Overview
Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): 6.26
Total Equity: $183.04B
Shares: 3,408,626,198
Total Debt: $193.04B
Cash: $172.59B
EBITDA: N/A
Total Debt: $193.04B
Cash: $172.59B
Revenue: $83.70B
Revenue: $83.70B
Revenue: $83.70B
Total Equity: $183.04B
Tax Rate: 15.2%
Equity: $183.04B
Total Debt: $193.04B
Cash: $172.59B
Current Liabilities: N/A
Long-Term Debt: $174.71B
Total Debt: $193.04B
Total Equity: $183.04B
Shares: 3,408,626,198
Shares: 3,408,626,198
CapEx: $0.00
Shares: 3,408,626,198
Stock Price: $86.45
Net Income: $21.34B
Industry Benchmarks
Income Statement (Annual)
Last updated: Aug 1, 2026 6:04pm (22d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $79.2B | $74.4B | $82.6B | $82.3B | $83.7B |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Expenses | $36.1B | $34.8B | $36.6B | $37.2B | $38.0B |
| Operating Income | — | — | — | — | — |
| Net Income | $22.1B | $13.7B | $19.1B | $19.7B | $21.3B |
| EBITDA | — | — | — | — | — |
| EPS | $5.13 | $3.30 | $4.88 | $5.43 | $6.34 |
| EPS (Diluted) | $5.08 | $3.27 | $4.83 | $5.37 | $6.26 |
Balance Sheet (Annual)
Last updated: Jul 31, 2026 9:12am (23d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $234.2B | $159.2B | $236.1B | $201.9B | $172.6B |
| Total Current Assets | — | — | — | — | — |
| Total Assets | $1.9T | $1.9T | $1.9T | $1.9T | $2.1T |
| Current Liabilities | — | — | — | — | — |
| Long-Term Debt | $160.7B | $174.9B | $207.6B | $173.1B | $174.7B |
| Total Liabilities | $1.8T | $1.7T | $1.7T | $1.7T | $2.0T |
| Total Equity | $190.1B | $181.9B | $187.4B | $181.1B | $183.0B |
| Retained Earnings | $180.3B | $187.6B | $201.1B | $214.2B | $228.9B |
Cash Flow (Annual)
Last updated: Aug 1, 2026 6:04pm (22d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$11.5B | $27.0B | $40.4B | $3.0B | -$19.0B |
| Capital Expenditure | — | — | — | — | — |
| Free Cash Flow | — | — | — | — | — |
| Acquisitions (net) | — | — | — | — | — |
| Net Debt Issued / (Repaid) | -$47.1B | -$19.6B | -$22.9B | -$55.6B | -$34.5B |
| Dividends Paid | -$2.4B | -$4.2B | -$4.8B | -$5.1B | -$5.4B |
| Stock Buybacks | -$14.5B | -$6.0B | -$11.9B | -$19.4B | -$17.5B |
| Net Change in Cash | -$30.4B | -$75.1B | $76.9B | -$34.2B | -$29.3B |
Growth Trends (YoY %)
Last updated: Aug 1, 2026 6:04pm (22d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | -6.1% | +11.1% | -0.4% | +1.7% |
| Gross Profit Growth | — | — | — | — |
| Operating Income Growth | — | — | — | — |
| Net Income Growth | -38.1% | +40.0% | +3.0% | +8.2% |
| EBITDA Growth | — | — | — | — |
Dividend History (Last 20)
Last updated: Jul 31, 2026 9:12am (23d ago)| Date | Dividend | Declaration | Record | Payment |
|---|---|---|---|---|
| 2026-05-08 | $0.45 | — | — | — |
| 2026-02-06 | $0.45 | — | — | — |
| 2025-11-07 | $0.45 | — | — | — |
| 2025-08-08 | $0.45 | — | — | — |
| 2025-05-09 | $0.40 | — | — | — |
| 2025-02-07 | $0.40 | — | — | — |
| 2024-11-08 | $0.40 | — | — | — |
| 2024-08-09 | $0.40 | — | — | — |
| 2024-05-09 | $0.35 | — | — | — |
| 2024-02-01 | $0.35 | — | — | — |
| 2023-11-02 | $0.35 | — | — | — |
| 2023-08-03 | $0.35 | — | — | — |
| 2023-05-04 | $0.30 | — | — | — |
| 2023-02-02 | $0.30 | — | — | — |
| 2022-11-03 | $0.30 | — | — | — |
| 2022-08-04 | $0.30 | — | — | — |
| 2022-05-05 | $0.25 | — | — | — |
| 2022-02-03 | $0.25 | — | — | — |
| 2021-11-04 | $0.20 | — | — | — |
| 2021-08-05 | $0.20 | — | — | — |
Deep Analysis
Narrative Economics
market-narrative step).
Claude Reading
The raw numbers tell a coherent story: WFC is grinding higher on earnings power without needing revenue growth. Net income progressed $19.14B → $19.72B → $21.34B over 2023-2025 (11.5% cumulative), while revenue crawled from $82.6B to $83.7B (1.3% cumulative). The quarterly NI trajectory — $4.91B, $5.11B, $5.08B, $4.89B, $5.49B, $5.59B, $5.36B, $5.25B — shows a genuine step-up starting mid-2025, roughly a 7-9% run-rate lift. That's the operating leverage story: cost-out and buybacks doing the work under the asset cap. ROE at 11.7% is still ~300-400bps below JPM (~17%) and BAC's normalized level, which is exactly what a 1.6x P/B vs. peers' 1.8-2.2x compensates for. At 13.8x earnings with a 2.08% yield and 25% payout, this is a capital-return story, not a growth story.
Where I push back on the prior models: the synthesis pegs fair value at $76.69 (signal-adjusted $79.14), implying 8.5% downside, then the market-forces layer calls it "fair value," and the thesis engine scores -4 (essentially neutral). These aren't inconsistent, but they collectively underweight the earnings acceleration visible in the last three quarters. If you annualize the 2025 Q2-Q4 run-rate (~$5.48B avg), you get ~$21.9B forward NI, which on 3.02B shares is ~$7.25 EPS — putting forward P/E closer to 11.9x, not 13.8x. That's cheap for a bank compounding earnings at 5-8% with buyback support, even under the asset cap. The synthesis fair value looks anchored to trailing multiples without crediting the Q3-Q4 2025 inflection.
The contrarian case is real and the thesis engine captures it: NII cliff risk as the Fed cuts is genuine — Q1 2026's $5.25B NI already ticked down from Q3 2025's $5.59B, which could be the leading edge. Deposit beta on the way down is untested at WFC's current mix, and the "asset cap lifts" catalyst has been perpetually 12-24 months away since 2018. Buffett trimmed and exited the entire position by 2022 — the smart-money endorsement narrative is stale. Credit normalization in CRE and card is a live 2026 risk that a 1% ROA bank feels immediately; a 20bps charge-off increase on ~$900B of loans is ~$1.4B pretax, meaningful against $21B NI. The single insider gift transaction is noise, not signal. The -$19B operating cash flow line is a bank-accounting artifact (trading assets, loan originations) — ignore it, but note that the models did too without flagging it.
I partially dissent from the synthesis's mild-overvaluation read. The Q3-Q4 2025 earnings step-up is real and forward multiples are ~12x, not 14x. But I also can't call this a table-pounder: the NII cliff and the Q1 2026 sequential dip are legitimate warning shots, and the asset-cap catalyst is uncorrelated with any timeline I trust. This is a coupon-clipper at $86 — 2% dividend plus 3-4% buyback yield plus mid-single-digit EPS growth gets you ~9-11% total return without a re-rating, and a re-rating to 1.8x P/B (peer parity minus a haircut) implies ~$97. Downside to $72-75 if the NII cliff materializes and credit normalizes simultaneously. Skew is modestly positive, not compellingly so. I'd own it, wouldn't chase it above $90, and would add aggressively below $78.
GPT Reading
At $86.45, Wells Fargo is not cheap enough for the constraints it still carries. The core numbers say “healthy large bank,” but not “mispriced bargain.” 2025 net income was $21.34B on $83.70B of revenue, up from $19.72B on $82.30B in 2024, so earnings grew 8.2% on just 1.7% revenue growth. That is respectable, but it also tells you the recent improvement is mostly operating leverage, mix, and reserve/expense discipline rather than true top-line acceleration. Over five years, revenue is basically flat versus 2021’s $79.17B and 2023’s $82.60B, while earnings only recently recovered back toward the 2021 peak of $22.11B. A bank at 13.8x earnings and 1.61x book with a 11.7% ROE is not obviously underpriced; if anything, the valuation assumes further normalization in returns that the actual reported ROE does not yet justify. Paying 1.6x book for a bank earning sub-12% on equity is fine if you expect a clean path to 13-15% ROE. I do not think the data here prove that path.
What stands out most is the mismatch between the stability of earnings and the mediocrity of franchise growth. Quarterly net income has been very steady, running from $4.89B to $5.59B over the last five reported quarters, with 2026 Q1 at $5.25B. That consistency deserves credit. But consistency alone should not command a premium multiple when revenue growth is running below 2% and the strategic ceiling remains visible. The market cap is $261.4B against $183.0B of equity, which is how you get that 1.6x P/B. For that to work, Wells needs either materially better growth, meaningfully higher capital return, or a step-up in sustainable profitability. The dividend yield is only 2.1% with a 25% payout ratio, so yes, there is room to distribute more capital, but that upside is already part of the standard bull case for every large bank with excess capital. It is not unique enough to justify chasing the stock at this level.
I also would not dismiss the ugly operating cash flow print as “just bank accounting” and move on. Yes, bank cash flow statements are noisy and far less useful than for industrials, but negative operating cash flow of $19.0B in 2025 alongside $172.6B of cash and $193.0B of debt reinforces the point that you should value this business on earning power and balance-sheet quality, not on simplistic cash metrics. On that basis, the company looks solid, not special. ROA of 0.99% is decent but not elite; ROE of 11.66% is improved but still not a premium-bank outcome. If Wells were at 1.2x-1.3x book, I would be more forgiving because you would be getting paid to wait for the rerating. At 1.6x book and nearly 3.5x sales, the wait is no longer cheap.
The best argument against my view is straightforward: Wells is still valued below the very best large-bank franchises, yet it is producing over $21B of annual profit, its quarterly earnings are unusually stable, and even modest improvement in efficiency or regulatory status could push ROE from 11.7% toward the mid-teens. If that happens, 13.8x earnings would look undemanding, especially with a low payout ratio enabling buybacks and dividend growth. A smart bull would also point out that 2025 earnings exceeded both 2024 and 2023 despite sluggish revenue, which suggests management has more control over expenses and capital allocation than skeptics admit. I weigh that differently because banks do not get infinite credit for expense discipline when revenue is stuck around $82-84B; eventually the valuation has to be earned through better franchise economics, not just cleaner execution.
What would change my mind is evidence that Wells can convert this earnings plateau into a higher-return bank without needing heroic assumptions. Specifically, I would want to see annual net income sustain above $23B, ROE move clearly above 13%, and revenue growth accelerate beyond the current 1-2% range while quarterly earnings remain around or above the recent $5.3B run rate. If those numbers arrive, then today’s 1.6x book could prove reasonable and even cheap. Conversely, if earnings drift back toward the 2024 level of roughly $19.7B as rates normalize or costs re-emerge, the stock should not be near the high $80s; on that downside setup, a valuation closer to 11-12x earnings and around 1.3x-1.4x book would be more appropriate.
Grok Reading
The numbers describe a franchise that has stopped shrinking but has not started growing. Revenue crawled from $82.30B in 2024 to $83.70B in 2025—a 1.7% lift that sits inside a five-year CAGR of just 0.7%. Net income did better, rising from $19.72B to $21.34B (+8.2% YoY), and the quarterly run-rate has stabilized near $5.2–5.6B, yet that earnings progress is almost entirely margin and mix rather than volume. ROE at 11.7% and ROA at 0.99% remain second-tier for a money-center bank; a 1.61× book multiple on that return is not a bargain, and the 13.8× earnings multiple looks even less so once the asset-cap constraint is treated as binding rather than temporary. Operating cash flow of –$19B in the latest annual period, even allowing for banking-statement noise, underscores that the balance-sheet engine is still being managed under regulatory handcuffs rather than compounding freely. At $86.45 the shares sit roughly 9% above the composite fair-value band of $77–79 that the quantitative stack produced; the market is already paying for an easing of constraints that has not yet appeared in the top line.
The only material positive signal in the raw data is earnings durability: net margin held at 25.5%, the payout ratio is a conservative 25%, and the dividend yield of 2.1% is covered without strain. Debt-to-equity of 1.05× and a cash pile nearly matching total debt keep solvency risk low. But none of that offsets the growth vacuum. A bank whose revenue has been essentially flat for three straight years while peers expand deposits and loans is not a compounder; it is a call option on regulatory forbearance. The “fallen-angel” narrative is doing real work here—the modest premium to model value is precisely the price of hope that the Fed will lift the asset cap inside the next 12–24 months. Until that hope converts into measurable loan growth and fee acceleration, the multiple deserves to stay compressed versus JPMorgan and Bank of America.
The strongest counter-argument is straightforward: remove the asset cap and the same deposit franchise and capital base can generate mid-single-digit revenue growth and push ROE toward 14–15%, which would re-rate the stock to 1.9–2.1× book and justify prices well above $100. Recent earnings growth of 8% and the absence of fresh compliance failures support the view that management has finally stabilized the ship; value investors (and Berkshire’s long-standing position) are underwriting exactly that path. I weigh this less heavily because the data still show zero evidence of the inflection—revenue CAGR remains sub-1%, and every quarter of delay erodes the present value of the upside while leaving the stock exposed to an NII compression if the rate cycle turns before relief arrives. Paying 13.8× for a capped, low-ROE bank is an expensive way to own that binary.
I would reverse to a constructive stance on two concrete triggers: (1) formal Fed removal or material loosening of the asset cap, or (2) two consecutive quarters of revenue growth above 4% YoY accompanied by ROE sustained above 13%. Absent either, the shares look 8–12% rich.
Big-3 Panel — where each AI stands
Claude — Second Response · fairly valued changed direction
VERDICT: Fairly valued at $86 — fair range $80-88, upside requires asset-cap relief or ROE >13%, add below $78, trim above $92
Both colleagues converge on ~$77-80 fair value, and their strongest shared argument is that revenue has been flat for three years, so the 2025 earnings step-up is expense/mix-driven and doesn't deserve a growth multiple. That's a fair critique of my "earnings acceleration" framing — I was annualizing three quarters of a run-rate lift and calling it forward earnings power, but GPT is right that expense discipline on a flat revenue base doesn't compound indefinitely. Eventually you either grow the top line or the operating leverage exhausts itself. My $7.25 forward EPS assumes the Q2-Q4 2025 run-rate holds, and the Q1 2026 tick down to $5.25B is at least consistent with their skepticism, not mine.
What doesn't move me: Grok's framing of WFC as "a call option on regulatory forbearance" priced at a premium. The math still says 11.9x forward earnings on my annualized run-rate, or 13.8x trailing — neither is a premium multiple for a bank with 25.5% net margins and a 25% payout ratio leaving room for buyback acceleration. Both colleagues anchor to 1.6x book on 11.7% ROE and call it full; I'd counter that JPM at 1.9-2.2x on 17% ROE implies a P/B-to-ROE ratio of ~0.12, while WFC at 1.6x/11.7% is ~0.14 — actually slightly *richer* per unit of ROE, which is the sharper version of their argument and one I should concede. That's the number that moved me most: on ROE-adjusted book, WFC isn't cheap versus JPM, it's marginally expensive.
I'm revising toward fairly valued, not overvalued. The coupon-clipper math (2% div + 3-4% buyback + 5% EPS growth = ~10% total return) still works at $86 without any re-rating, so I can't call it overvalued outright — but my $92-97 fair value overstated the case. Fair value $80-88, with the same add-below-$78 discipline.
GPT — Second Response · overvalued revised
VERDICT: Slightly overvalued at $86.45; fair value modestly higher than my first pass at roughly $78-$82, with upside only if ROE clears 13% or the asset cap is lifted.
Claude’s note made me re-check the one argument that could have moved me: the idea that trailing 13.8x is the wrong lens because Q3–Q4 2025 marked a real earnings step-up, making the stock closer to ~12x forward EPS. I agree that annualizing the stronger late-2025 run rate produces a friendlier multiple, and I underweighted that in my first pass. But I don’t think the evidence is strong enough to revise upward because the supposed inflection is already less clean once you include 2026 Q1 at $5.25B after $5.59B/$5.36B. That still supports “solid earnings power,” just not a durable re-rating case yet. Put differently: Claude improved the multiple argument, but not the durability argument. If this is a cost-out/buyback story under an asset cap, then ~12x forward earnings is reasonable; it is not automatically cheap when revenue remains pinned around $82-84B and ROE is still only 11.7%.
Grok largely reinforced my original framing, especially on the core mismatch between valuation and franchise economics. What failed to move me from the bullish side is the peer-relative P/B defense: saying 1.6x book is acceptable because JPM/BAC trade higher only works if Wells is clearly on a path toward their return profile. The current data still do not show that. Both colleagues acknowledge the same two risks I care most about: asset-cap relief remains speculative in timing, and NII/credit normalization could interrupt the late-2025 earnings lift before Wells ever earns a premium multiple. So I’ll narrow the degree of overvaluation versus my first read, because the forward earnings point is fair, but I still land on “slightly rich” rather than undervalued. I’d need either a confirmed cap lift or sustained >13% ROE with better revenue growth before paying confidently above the mid-$80s.
Grok — Second Response · overvalued revised
VERDICT: Modestly overvalued at $86.45 vs ~$81–83 fair value; flat revenue and 11.7% ROE still do not support the multiple
Claude’s forward-earnings reframing is the cleanest challenge to my first read: annualizing the mid-to-late 2025 run-rate near $5.48 B produces roughly $7.25 EPS and an 11.9× multiple rather than the trailing 13.8×. That arithmetic is correct on its face and forces a modest upward revision in my composite fair-value band from $77–79 toward $80–83. Yet the same data undercut the rest of the bull case. Q1 2026 already printed $5.25 B, a sequential fade that sits inside the very window Claude cites as the “inflection.” Revenue remains capped at a 0.7 % five-year CAGR; the earnings lift is still almost pure operating leverage and buybacks. Paying even 12× for a franchise whose ROE is stuck at 11.7 % and whose top line has not expanded in three years is not a discount—it is merely less expensive hope.
GPT’s insistence that ROE must clear 13 % and revenue must accelerate beyond 1–2 % before 1.6× book is justified lands exactly where my original work did. The negative operating-cash-flow print is noise, but the underlying point is not: the balance sheet is still being run under an asset ceiling, not compounding. Claude’s peer-re-rating target of $92–97 therefore requires the precise catalyst (cap removal or sustained mid-single-digit loan growth) that has been “12–24 months away” since 2018. Until that evidence appears, the skew stays modestly negative. I am not drifting; Claude’s multiple math moved the fair-value pin by a few dollars, but the growth vacuum and sub-par ROE keep the shares 5–8 % rich at $86.45.
Advanced Analysis Forensic deep-dive · separate lenses
Revenue is flat-to-slightly-growing (79.2B in 2021 to 83.7B in 2025) while net income has recovered to 21.3B, indicating a mature, scaled franchise that is executing on cost and capital return post-asset-cap era. Diluted shares have fallen from 4.35B to 3.41B (-5.9% CAGR) with buybacks running ~12x SBC, so per-share economics are meaningfully compounding even without top-line growth. This is classic mature-earner behavior for a systemically important US bank. That said, cash-flow signals are volatile and weak on the surface: FCF swung from +40.4B (2023) to +3.0B (2024) to -19.0B (2025), and OCF/NI at 0.57x plus 0.5% accruals hint that reported earnings are running ahead of cash conversion. For a bank these figures are heavily distorted by trading assets, loan growth and deposit flows rather than true operating quality, and the Altman Z of 0.27 is largely a bank-model artifact (Z is not designed for banks). Still, the pattern warrants scrutiny. Net debt of -20.4B against 172.6B liquid is normal for a G-SIB and does not indicate stress. No directional insider trades on the tape (only a gift), so no signal there. Overall this reads as a solidly healthy, well-capitalized franchise with disciplined share count management, but not a fortress: regulatory overhang, cyclical credit exposure, and messy cash-conversion optics keep it from the top tier.
Verify before trusting this (7)
- Regulatory status: whether the Fed asset cap has been fully lifted and any remaining consent-order constraints
- CET1 ratio, liquidity coverage ratio, and stress-test (CCAR) results to confirm capital adequacy
- Net charge-off trends and allowance for credit losses coverage, especially in CRE office exposure
- Deposit mix and cost of funds trajectory vs. peers
- Detail behind the 2025 FCF swing to -19B (trading assets, loan growth, or securities portfolio activity)
- Segment profitability: consumer banking vs. commercial vs. wealth vs. corporate/investment banking
- Any ongoing legal or DOJ/CFPB matters that could produce large reserves
The e2e composite pegs fair value at $76.69 and the signal-adjusted FV at $79.14, versus a market price of $86.45 - roughly 8-10% overpriced, not cheap. The anchored-PE method corroborates the composite at $76.69, so there is no runaway single-method to discount; the deserved value read is coherent. With a poor earnings-quality haircut hint (-2, multiple red flags), the deserved price should skew lower rather than higher, widening the gap. Company quality is Solid but not exceptional (score 32) - a competent G-SIB compounding per share via buybacks on a flat top line. That supports a market-multiple, not a premium multiple, so the case for paying above composite FV is weak. The fallen-angel narrative (regulatory overhang lifting, capital return) appears already reflected in the price; the bull case needs execution the management team has not consistently delivered. Net: this is a fully-priced mature bank, not a mispricing. I would want a mid-70s handle before valuation alone justifies action.
Verify before trusting this (4)
- Whether the asset cap is formally lifted (materially changes NIM and loan-growth trajectory and thus deserved PE)
- Normalized ROTCE run-rate vs peers to confirm the anchored-PE multiple is appropriate
- Provision/credit trends in next 10-Q that could validate or invalidate the earnings-quality red flags
- Buyback pace and CET1 headroom guiding forward EPS accretion
The macro tape is mildly constructive (VIX 16, S&P near highs, regime score +22) but rates at 4.68% and a stretched market PE 26.2 keep a lid on multiple expansion for big banks. With beta 0.92, WFC absorbs macro moves roughly in line with the tape rather than amplifying them, and as a deposit-rich diversified bank it is neither the beneficiary of the dominant AI narrative nor a direct victim of it. The active story is a moderate-intensity, moderate-durability 'fallen angel stabilization' - not a cult trade, not a collapse - which by definition produces modest pressure in either direction. News flow is quiet and constructive on the margin: Wells is being cited as a research house (setting targets on MSFT, SNOW) rather than being the subject of negative headlines, and a Barron's piece flags a recruiting comeback in wealth management - small tailwind signals that reinforce the stabilization narrative without igniting it. There is no target-revision wave, no scandal re-emergence, no sector rotation actively hitting diversified banks. Net: the non-fundamental pressure on WFC right now is genuinely muted - a slight positive drift from narrative repair and analyst-brand visibility, offset by a rates/PE macro that caps enthusiasm for financials.
Verify before trusting this (4)
- Any resurfacing of asset-cap or consent-order news that would reignite the scandal narrative
- Sector rotation into financials on curve steepening or bank earnings beats
- Analyst target-revision cluster on WFC specifically (currently absent)
- Wealth management advisor headcount trend - is the recruiting comeback real
This lens hasn't been run for this ticker yet.
When we made this prediction on Aug 2, 2026, WFC was $86.45. We expect it to be $81.50 by Feb 2027, and we consider it great value under $72.00. This is an early model (v0.6.0) — the direction is more reliable than the exact price. Made Aug 2, 2026.
Blue is our prediction, starting the day we made it. Grey is a slower route to the same place — the same destination, taking longer. Black is the actual price, so you can see how we are doing.